PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, and only for that. It works centrally on brain melanocortin receptors, not on blood flow like Viagra. Widely used off-label in men, but the male evidence is thin, and outside the US it is not an approved medicine.
Oxytocin is a nonapeptide hormone made in the hypothalamus. The synthetic injectable form (Syntocinon in the UK, Pitocin in the US) is a long-approved hospital medicine used to induce labour, augment contractions and prevent postpartum bleeding. The popular "love hormone" framing of intranasal oxytocin for bonding, autism and anxiety is not an approved use and the trial evidence is largely disappointing.
Both peptides share an evidence grade of A. The right choice depends less on the data and more on what you're trying to do, PT-141 for hypoactive sexual desire disorder (hsdd) in premenopausal women, Oxytocin for induction and augmentation of labour.
FDA-approved June 2019 as Vyleesi for the as-needed treatment of acquired, generalised HSDD in premenopausal women. Based on the two RECONNECT phase 3 trials (Kingsberg et al. 2019). Effect size is real but modest, a treatment-vs-placebo difference of roughly 0.35 points on the FSFI-Desire scale and 0.27 on FSDS-DAO Q13, and around 18% of patients on active treatment discontinued because of nausea or other side effects.
Earlier phase 2 work in the 2000s with intranasal bremelanotide in men with ED showed some signal but was discontinued during development because of dose-related transient blood-pressure increases. There are no large modern phase 3 trials in men. Off-label prescribing and very widespread gray-market use exists, but the evidence for the male indication is several rungs below the female one.
Palatin and academic groups have explored melanocortin agonism for reperfusion injury and shock; this remains preclinical / very early clinical and is not a near-term indication.
FDA-approved (Pitocin) and EMA/MHRA-approved (Syntocinon) for medically indicated induction of labour and augmentation of inadequate uterine contractions. Used hospital-wide as a continuous IV infusion under fetal monitoring.
First-line uterotonic for active management of the third stage of labour and for treating postpartum haemorrhage. Recommended by the WHO, NICE (NG235) and most national obstetric guidelines.
Approved adjunct after caesarean section to assist uterine contraction and reduce blood loss.
The dose-limiting side effect is nausea, reported by about 40% of patients in the long-term extension; flushing (~20%) and headache (~12%) are also common. Around 18% of treated patients in RECONNECT discontinued because of adverse events, versus 2% on placebo, a meaningful real-world signal. Bremelanotide transiently increases blood pressure (typically peaking 2–4 hours after a dose) and reduces heart rate, and is therefore contraindicated in uncontrolled hypertension or known cardiovascular disease. With repeat dosing, focal hyperpigmentation, darkening of the face, gums or breasts, can occur, mediated by off-target MC1R activity; it may not fully resolve after stopping. The phase-3 safety dataset is overwhelmingly in women; the safety profile for chronic male use is not characterised at FDA-grade. Not for use in pregnancy.
In hospital, oxytocin has a well-characterised safety profile but is not a benign drug. Excess uterine stimulation can cause tachysystole, uterine rupture (especially with a scarred uterus) and fetal distress; that is why the infusion is titrated against contractions and fetal monitoring. Oxytocin has a structural similarity to vasopressin and at high cumulative doses with large free-water infusions can cause water retention and hyponatraemia, occasionally severe. Cardiovascular effects (hypotension, tachycardia) are dose-related and more pronounced with rapid IV bolus, so the medicine is given as an infusion. Anaphylaxis is rare. For the unlicensed intranasal "wellness" products, the principal safety problem is not the molecule itself, intranasal oxytocin in trials has generally been well tolerated short-term, but the supply chain: research-chemical and compounded preparations have unverified content, sterility and labelling, and they are not regulated like the hospital drug.
Both peptides share an evidence grade of A. The right choice depends less on the data and more on what you're trying to do, PT-141 for hypoactive sexual desire disorder (hsdd) in premenopausal women, Oxytocin for induction and augmentation of labour.
Pepwyse comparison pages are generated from the same structured data behind each peptide profile. Want a different head-to-head? Use the compare picker or ask PT-141 directly via the Ask-Peppy button. Not medical advice, see how we grade evidence.